Introducing Absentia’s AI Predictive Drug-Induced Cardiotoxicity Module
Absentia combines patient outcome data with preclinical mechanistic readouts to surface cardiotoxicity risk earlier—giving scientists quantitative risk, mechanistic context, and weight-of-evidence support for IND and drug development decisions.
Module
Digital Cardiac Model
Status
Accepted into FDA’s ISTAND qualification pathway
Inputs
Patient outcome data, preclinical mechanistic readouts
Outputs
Quantitative risk, mechanistic context, weight-of-evidence support
See cardiac risk before it becomes a late-stage surprise.
Cardiotoxicity can become visible when the options for addressing it are already narrowing. Absentia is designed to surface potential risk earlier—while teams still have room to act.
of small molecules that fail in clinical development due to toxicity are attributed to cardiotoxicity.
Cardiac safety goes beyond a single endpoint.
hERG screening remains an important checkpoint for electrophysiological risk. But drug-induced cardiotoxicity can also emerge through structural and functional/hemodynamic failure modes. Absentia is designed to bring these signals together within one predictive framework.
Failure mode
Electrophysiological
Evaluate signals related to cardiac electrophysiology.
Structural
Predict morphological cardiac liabilities.
Functional / Hemodynamic
Add context around functional and hemodynamic risk.
hERG remains a valuable checkpoint. The cardiac model is designed to evaluate the broader mechanistic picture alongside it.
FDA ISTAND acceptance is the latest step in Absentia’s predictive safety platform.
Following its Digital Liver milestone, Absentia’s AI-driven Digital Cardiac Model has also been accepted into FDA’s ISTAND qualification pathway—advancing a more complete approach to evaluating one of drug development’s most common toxicity risks.
01 Established
Liver
Digital Liver, the first organ-system proof point in the platform.
02 Now
Cardiac
The AI-driven Digital Cardiac Model, accepted into FDA’s ISTAND qualification pathway.
03 Output
Multi-organ safety
A broader predictive safety platform across organ systems.
Interested in evaluating Absentia’s cardiac safety capabilities?
Whether you’re evaluating a compound, exploring a scientific collaboration, or looking at new approaches to predictive safety, we’d be glad to talk.
